Dr. Mato Discusses the Safety and Efficacy of Umbralisib in CLL

Anthony R. Mato, MD
Published: Sunday, Jun 17, 2018



Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia (CLL).

This phase II study evaluated the safety and efficacy of the next-generation PI3K inhibitor umbralisib in patients with CLL who are intolerant to prior therapy with either a Bruton’s kinase inhibitor, or a PI3K inhibitor. In results presented during the 2018 European Hematology Association Congress, umbralisib showed to be safe in effective in this population.

The toxicity profile was quite impressive Mato says, with relatively few grade 3/4 events. The primary endpoint was progression-free survival (PFS) with a median follow-up of 9.5 months. The median PFS has not yet been reached. There has only been 1 death on the study, and 6 patients had to discontinue treatment due to adverse events.


Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia (CLL).

This phase II study evaluated the safety and efficacy of the next-generation PI3K inhibitor umbralisib in patients with CLL who are intolerant to prior therapy with either a Bruton’s kinase inhibitor, or a PI3K inhibitor. In results presented during the 2018 European Hematology Association Congress, umbralisib showed to be safe in effective in this population.

The toxicity profile was quite impressive Mato says, with relatively few grade 3/4 events. The primary endpoint was progression-free survival (PFS) with a median follow-up of 9.5 months. The median PFS has not yet been reached. There has only been 1 death on the study, and 6 patients had to discontinue treatment due to adverse events.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x